Scancell (LON:SCLP) Trading Up 29.8% – Should You Buy?

Scancell Holdings plc (LON:SCLP)’s stock price traded up 29.8% during mid-day trading on Monday . The company traded as high as GBX 11.49 ($0.15) and last traded at GBX 11 ($0.14). 10,149,031 shares traded hands during trading, an increase of 1,037% from the average session volume of 892,663 shares. The stock had previously closed at GBX 8.48 ($0.11).

Scancell Stock Performance

The company has a debt-to-equity ratio of -566.79, a quick ratio of 13.01 and a current ratio of 3.42. The company’s 50-day moving average price is GBX 8.43 and its 200 day moving average price is GBX 10.88. The stock has a market capitalization of £113.93 million, a PE ratio of -16.86 and a beta of 0.35.

Scancell (LON:SCLP) last posted its quarterly earnings data on Thursday, January 30th. The company reported GBX (1.35) (($0.02)) EPS for the quarter. On average, equities research analysts expect that Scancell Holdings plc will post -2.5361112 earnings per share for the current fiscal year.

Scancell Company Profile

Scancell (LSE:SCLP) is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers.

Scancell has developed a pipeline of ‘off-the-shelf’ vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.